CareCredit Is Now Integrated Into Planet DDS Denticon Practice Management Software

NEW INTEGRATION MAKES IT EASIER TO HELP MORE PATIENTS GET CARE

PR Newswire

COSTA MESA, Calif., May 17, 2021 /PRNewswire/ — CareCredit, a Synchrony (NYSE:SYF) solution and a leading provider of promotional financing for patients, is now integrated into Planet DDS Denticon practice management software. The new integration is designed to help practice teams save time, increase productivity and provide patients with a financing option in order to make it easier for them to move forward with recommended treatment.

The integration features CareCredit’s Quickscreen®, which enables teams to easily identify patients who are pre-approved or that already have an existing CareCredit credit card — even before they visit the office. Knowing who is likely to be approved for CareCredit and who already has a card, can help make the financial conversation easier. Additionally, practices can now process transactions directly from the Patient Account Screen and have them automatically post back to the ledger, helping to save time and minimize human error. Helping patients apply for CareCredit is also easier. When a patient wants to apply, the patient information is automatically transferred to the CareCredit application, so all the team has to do is complete a few fields of information from the patient and click “submit” to receive a credit decision within seconds.

“Providing solutions that can help practices streamline processes, enhance productivity and help patients move forward with care, is imperative — especially in today’s environment” said Doug Hammond, SVP & GM of CareCredit. “CareCredit’s integration into Denticon practice management software is an important part of our ongoing commitment to respond to the needs of the dental community by giving practices easy access to a financing solution that helps remove barriers to recommended care.”

“A direct integration with CareCredit will give our clients’ patients additional financing options, opening up opportunities for them to receive needed care that they may have declined otherwise.” said Eric Giesecke, CEO of Denticon. “Denticon users will be able to check patients’ CareCredit status within Denticon and submit applications to receive an immediate credit decision. We’re very excited about what this new partnership will bring to our clients and to their patients.”

Practice teams who accept CareCredit and use Denticon practice management software should contact Denticon for a demo of the integration features by calling 800-861-5098 or visiting https://info.planetdds.com/denticon/carecreditintegration. Practices not currently accepting CareCredit but are interested in helping maximize treatment acceptance by becoming a part of the CareCredit network should call 800 859-9975 or visit https://www.carecredit.com/providercenter/ to learn more or enroll.  

About CareCredit
CareCredit, a Synchrony solution, is a leading provider of promotional financing to consumers for health, veterinary and personal care procedures, services and products. For more than 30 years, CareCredit has helped millions of people by offering special financing options with convenient monthly payments. CareCredit is accepted at more than 240,000 locations for a wide variety of health and wellness procedures, treatments, products and services.

About Synchrony
Synchrony (NYSE: SYF) is a premier consumer financial services company. We deliver a wide range of specialized financing programs, as well as innovative consumer banking products, across key industries including digital, retail, home, auto, travel, health and pet. Synchrony enables our partners to grow sales and loyalty with consumers. We are one of the largest issuers of private label credit cards in the United States; we also offer co-branded products, installment loans and consumer financing products for small- and medium-sized businesses, as well as healthcare providers. Synchrony is changing what’s possible through our digital capabilities, deep industry expertise, actionable data insights, frictionless customer experience and customized financing solutions. For more information, visit www.synchrony.com and Twitter: @Synchrony

About Planet DDS
Planet DDS is a solutions company for dental practices. Through its innovative solutions, including cloud-based practice management and imaging software, Planet DDS helps clients improve the efficiency and economics of their dental practices. Planet DDS was the first to the cloud with its top-rated practice management solution, Denticon. Its all-in-one, cloud-based Denticon software is the go-to solution for dental practices of all sizes. Denticon’s robust capabilities include patient-facing features, patient communications, analytics, and revenue cycle management. Planet DDS recently acquired Apteryx Imaging, a company with over 20-years of experience providing dental health professionals with advanced diagnostic imaging software. Planet DDS continues to lead in the cloud-software space, now also offering Apteryx XVWeb, a cloud-based imaging software that delivers state-of-the-art clinical image capture, visualization, analysis, backup, and secure data sharing to dentists and oral health specialists. Trusted by both top DSOs and single location offices looking to scale, Planet DDS offers robust, comprehensive solutions for practices of all sizes. Planet DDS has successfully converted thousands of dental practices from legacy desktop software to the cloud. To learn more about Planet DDS and Denticon, visit https://www.planetdds.com/.

CONTACTS:
CareCredit: Michelle Blaya at [email protected] 
Planet DDS:  David Means at [email protected]

©2021 Synchrony Bank

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/carecredit-is-now-integrated-into-planet-dds-denticon-practice-management-software-301291401.html

SOURCE Synchrony

Patient Discovery Appoints Theresa West as Chief Commercial Officer

Healthcare Technology Veteran Joins Patient Discovery to Accelerate Growth of Real-World Data Powered Patient-Provider Engagement Platform

PR Newswire

BOSTON, May 17, 2021 /PRNewswire/ — Patient Discovery Solutions, a leader in patient-provider engagement technologies which harness the power of real-world data to achieve better health outcomes, today announced the appointment of Theresa West to the position of Chief Commercial Officer. In this newly created role, Ms. West will lead all aspects of Patient Discovery’s commercialization efforts, leveraging more than 20 years of healthcare technology experience, encompassing sales, marketing and new product launches.

“We are extremely pleased to welcome Theresa to Patient Discovery, and we look forward to having her accelerate and expand our growth across healthcare systems, insurers and pharma,” said Jason Shore, Chief Executive and Co-Founder of Patient Discovery. “Our goal is to build Patient Discovery into one of the next great healthcare technology companies and the addition of best-in-class commercial talent is a key ingredient.”

Ms. West brings extensive leadership experience to the role of Chief Commercial Officer at Patient Discovery Solutions. She previously served as National Vice President, Community Strategy and Solutions at Signify Health (NYSE: SGFY) which acquired TAVHealth, where she grew annual sales from a bootstrapped start-up to $15MM in annual sales in 5 years. Prior to TAVHealth, Ms. West held leadership roles at Abbot Laboratories and McKesson Corporation.

“The team at Patient Discovery shares a commitment to delivering an exceptional care experience while also having a profound impact on health outcomes,” commented Ms. West. “I look forward to leading Patient Discovery’s commercial organization as we accelerate growth with innovative technologies at the heart of solving some of the most important problems in healthcare.”

About Patient Discovery

Patient Discovery’s mission is to transform the way all patients are understood, supported and treated, and provide a platform for patients’ real-world experiences to be integrated into decision-making throughout the entire healthcare ecosystem.

Our patient-provider engagement platform brings to the forefront non-clinical factors that both allow providers to efficiently create better patient-centric and standard care plans, and enable health systems, pharma, and payers to effectively make informed decisions based on aggregated, real-world patient insights.

For more information, please visit the company’s website at www.patientdiscovery.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/patient-discovery-appoints-theresa-west-as-chief-commercial-officer-301292552.html

SOURCE Patient Discovery

Trinseo Offers Recycled Polystyrene for Food Contact Applications

Trinseo Offers Recycled Polystyrene for Food Contact Applications

Material Demonstrates Circular Economy in Action

BERWYN, Pa.–(BUSINESS WIRE)–Trinseo (NYSE: TSE), a global materials company and manufacturer of plastics, latex binders, and synthetic rubber announced that it can now supply recycled polystyrene (rPS) for food contact applications with the launch of the first yogurt pot integrating rPS, now on shelves in France.

The material –Trinseo’s STYRON™ CO2RE™ CR55 Polystyrene Resin — contains 55 percent recycled content resulting from depolymerization, and is part of the company’s STYRON™ CO2RE™ portfolio of recycled polystyrene (PS) grades. PS is a unique plastic in that it can be depolymerized to its monomer level and can be reused along with virgin content with no distinction between the two. Consequently, polystyrene recycled via this method can be used widely in high quality, demanding applications including consumer electronics, packaging, household durables … and even food contact applications.

According to Trinseo’s Plastics Circularity Manager, Julien Renvoise, STYRON™ CO2RE™ CR55 Polystyrene supports a circular economy. “This is a real-world example of how polystyrene can be reclaimed and reused. Because of the simplicity of the chemistry, polystyrene is actually infinitely recyclable meaning that it never has to end up as consumer waste in a landfill again, but will preserve its value as a material that can be constantly recycled for new applications.”

This innovation is the result of a collaboration between Trinseo and Intraplàs, an expert in extrusion of plastic sheets for the food industry. Together the companies supply and transform the certified recycled polystyrene raw material used by Yoplait in France to launch the first pot made with 50 percent of rPS in the French market.

To measure the impact of rPS, Trinseo has partnered with Styrenics Circular Solutions on a lifecycle assessment comparing PS produced with 100 percent fossil-based material with material containing depolymerized content. Initial results of this assessment, considering potential end-of-life incineration, have shown a favorable environmental footprint; final results are expected in June.

STYRON™ CO2RE™ CR55 Polystyrene, produced from depolymerization, is part of Trinseo’s portfolio of sustainable polystyrene and is ISCC+ certified according to mass balance processes. The company also recycles polystyrene via a dissolution method, a physical recycling process that doesn’t change the chemistry of the recyclate and can be used for food contact applications using a mono-material multi-layer structure. The company currently is supported with sourcing from U.S. and from Europe and recently announced plans to build a dedicated plant at its Tessenderlo, Belgium location with technology provided by Recycling Technologies (RT), adding 15,000 tons of polystyrene feedstock into the European marketplace by 2023. An intermediate small-scale pilot plant is scheduled to be operational in the UK in 2022 to further optimize the RT technology.

About Trinseo

Trinseo (NYSE:TSE) is a global materials solutions provider and manufacturer of plastics, latex binders, and synthetic rubber with a focus on delivering innovative, sustainable, and value-creating products that are intrinsic to our daily lives. Trinseo is dedicated to making a positive impact on society by partnering with like-minded stakeholders, and supporting the sustainability goals of our customers in a wide range of end-markets including automotive, consumer electronics, appliances, medical devices, packaging, footwear, carpet, paper and board, building and construction, and tires. Trinseo had approximately $3.0 billion in net sales in 2020. With the May 2021 acquisition of the PMMA business, the Company has 24 manufacturing sites around the world, and approximately 3,500 employees. For more information, please visit: www.trinseo.com.

Cautionary Note on Forward-Looking Statements

This press release may contain forward-looking statements including, without limitation, statements concerning plans, objectives, goals, projections, strategies, future events or performance, and underlying assumptions and other statements, which are not statements of historical facts or guarantees or assurances of future performance. Forward-looking statements may be identified by the use of words like “expect,” “anticipate,” “intend,” “forecast,” “outlook,” “will,” “may,” “might,” “see,” “tend,” “assume,” “potential,” “likely,” “target,” “plan,” “contemplate,” “seek,” “attempt,” “should,” “could,” “would” or expressions of similar meaning. Forward-looking statements reflect management’s evaluation of information currently available and are based on our current expectations and assumptions regarding estimated and future results of operations, business strategies, competitive position, industry environment and potential growth opportunities and cost synergies relating to the acquisition of the MMA and PMMA businesses from Arkema S.A.;our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Factors that might cause such a difference include, but are not limited to,our ability to successfully integrate the acquired MMA and PMMA businesses, generate expected cost savings and synergies, maintain relationships with customers, retain key employees and profitably grow the business; and those factors discussed in our Annual Report on Form 10-K, under Part I, Item 1A —”Risk Factors” and elsewhere in our other reports, filings and furnishings made with the U.S. Securities and Exchange Commission from time to time. As a result of these or other factors, our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

Editorial Information:

Paula Biskup

Trinseo

248-802-2783

[email protected]

KEYWORDS: United States North America Pennsylvania

INDUSTRY KEYWORDS: Packaging Chemicals/Plastics Automotive Other Automotive Manufacturing Textiles Steel

MEDIA:

Logo
Logo

Alchip Technology Set Record Q1 Revenue, Operating Income, Net Earnings & EPS

Guides for Record 2021 Revenue

Taipei, Taiwan, May 17, 2021 (GLOBE NEWSWIRE) — Taipei, Taiwan May 17, 2021 – Alchip Technologies first quarter of 2021 financial results set records for revenue, operating income, net earns and earnings per share.  This is the second consecutive year and the fifth quarter in a row that the company has reported record financial results.

 

First quarter revenue was $93.7 million, up 99 percent from year-ago revenue of $50.5 million and up 41% over fourth quarter 2020 revenue of $66.4 million. At the same, first quarter operating income was reported at $17.6 million, a whopping 280 percent increase over first quarter 2020 results of and a 113 percent increase over Q4 2020’s $8.3 million.

 

First quarter net income of $13.7 million also set records, exceeding 2020 results of $5.8 million by 196 percent and Q4 2020 net income of $8.1 million by 67 percent.  Earnings per share for the quarter was NT5.7.

 

Alchip is traded on the Taiwan stock exchange.  The company is extremely well respected in North America, Japan, Israel, Taiwan and China for its high-performance ASIC design methodology, flexible business model, best-in-class IP portfolio and advanced packaging technology expertise. 

 

For more information on Alchip, go to www.alchip.com.

 

-30-

 

About Alchip

Alchip Technologies Ltd, headquartered in Taipei, Taiwan, is a leading global provider of silicon design and production services for system companies developing complex and high-volume ASICs and SoCs.   The company was founded by semiconductor veterans from Silicon Valley and Japan in 2003 and provides faster time-to-market and cost-effective solutions for SoC design at mainstream and advanced, including 7nm processes. Customers include global leaders in AI, HPC/supercomputer, mobile phones, entertainment device, networking equipment and other electronic product categories. Alchip is listed on the Taiwan Stock Exchange (TWSE: 3661) and is a TSMC-certified Value Chain Aggregator.

 

###

 

Media contact                                               

Chuck Byers                                                                                                                                      

chuck_byers@alchip.com

+1-408-310-9244

Attachment



Charles Byers
Alchip Technolgies 
+ (408)-310-9244
[email protected]

EastGate Biotech Corp. Enters Into a 3-way International Distribution Agreement With Dr. Upadhyay Vedic Research Laboratories and ImmunoJuvenate, Inc.

The terms of the distribution agreement allows ImmunoJuvenate to market an entire product catalogue under Private label in the United States, Canada and international markets

WEST CALDWELL, NJ and TORONTO, ON, May 17, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — EastGate Biotech Corp. (OTC: Expert Markets: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced today that the company has entered into a three-way international distribution agreement with Dr. Upadhyay Vedic Research Laboratories of India and US-based ImmunoJuvenate Inc. for the marketing of Vedic Research Laboratories’ natural and ayurvedic product catalogue. While the marketing agreement will initially focus on Vedic’s immunity-boosting product it will expand to seven other products serving other treatment areas.  

The exclusive marketing agreement include distribution within the United States, Canada, Latin and South America, Europe, Africa and some S. East Asian countries.

“ImmunoJuvenate, Inc. is excited to partner with EastGate Biotech and specifically with Vedic Research Laboratories and its line of products,” stated Dr. Umer Hafeez, Chief Executive Officer of ImmunoJuvenate. “We, at ImmunoJuvenate, are looking forward to collaborating and promoting the products using social media, our corporate website, and our Task Force sales teams. Individuals may also earn complimentary product and many other perks via peer-to-peer direct sales. Our Task Force sales teams are provided full education and training in product effectiveness and sales techniques, allowing for consistent wholesale orders for small business and retail markets. The Task Force members, with exceptional sale skills and who consistently meet and/or exceed required product quota, are given increased opportunity to expand our Task Force by adding locations and territories to make this a true career path. 

“We intend to promote these All Natural Herbal based products designed and proven to promote the rejuvenation of the body defense and immunity to external organisms worldwide.  Be sure to visit us at ImmunoJuvenate.com for more comprehensive information.  Also be sure to visit ImmunoJuvenate on FaceBook, Instragram and LinkedIn,” continued Dr. Hafeez.

“On the back of a collaboration with Dr. Lalit Upadhyay of Vedic Research I am pleased that we were able to introduce this product catalogue and negotiate this distribution partnership with ImmunoJuvenate”, says Rose C. Perri, Chief Executive Officer of EastGate Biotech Corp.  “We wish to align the company with good quality products that enhance the lives of patients or customers and that can financially assist in driving EastGate’s R&D efforts with a focus on Insugin, liquid insulin mouth rinse.  We were impressed with the ImmunoJuvenate team in terms of their rapid decision making and strategic plans and look forward to working together,” concluded Rose C. Perri.

“I am excited about this partnership with EastGate Biotech and ImmunoJuvenate,” says Dr. Lalit Upadhyay of Vedic Research Laboratories. “I appreciate that they recognized the quality of my product catalogue for which I had spent many years developing and testing to ensure the best results for specific health ailments. During these trying times it has become more important for individuals to spend time on improving their immunity and other health areas and with ImmunoJuvenate’s marketing expertise we will be able to spread the word wide,” concluded Dr. Lalit Uphadhyay.

About EastGate Biotech

EastGate Biotech focuses on innovative technological developments and produces and distributes innovative drug compounds and healthy nutraceuticals that are based on natural therapies absorbed by the body. We utilize advanced nanotechnologies and alternative delivery systems that take difficult to deliver compounds and deliver them using our nanotechnology platform which ultimately increase the bioavailability to the body. Using our methods of delivery provides healthy alternatives to conventional pharmaceuticals that all-too-often create dangerous side-effects and unexpected consequences for those trying to attain and maintain a healthy lifestyle. 

Cautionary statement on forward-looking information

All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, including the provisions for “safe harbor” under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.

The words “anticipates”, “plans”, “expects”, “indicate”, “intend”, “scheduled”, “estimates”, “forecasts”, “focus”, “guidance”, “initiative”, “model”, “methodology”, “outlook”, “potential”, “projected”, “pursue”, “strategy”, “study”, “targets”, or “believes”, or variations of or similar such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, or “should”, “might”, or “way forward”, “will be taken”, “will occur” or “will be achieved” and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Rose Perri 
1-647-692-0652 
Email: [email protected]
Website: www.EastGateBiotech.com
SOURCE: EastGate Biotech Corp. 



Dynamic Funds announces May 2021 cash distributions for Dynamic Active ETFs

Canada NewsWire

TORONTO, May 17, 2021 /CNW/ – Dynamic Funds today announced the May 2021 cash distributions for two of the Dynamic Active ETFs listed on the TSX, which pay on a monthly basis. Unitholders of record on May 25, 2021 will receive cash distributions for the respective ETFs payable on May 28, 2021. The details of the cash distribution amounts per unit are as follows:


Dynamic Active ETF


Ticker symbol
 

(TSX)


Cash distribution
per unit ($)


Distribution
frequency

Dynamic Active International Dividend ETF

DXW

0.058

Monthly

Dynamic Active Retirement Income+ ETF

DXR

0.083

Monthly

For more information about these and the other Dynamic Active ETFs, please visit Dynamic.ca/ETF.

Commissions, management fees and expenses all may be associated with investments in exchange-traded funds (ETFs). Please read the prospectus before investing. The securities held by the ETFs can change at any time without notice. Investments in ETFs are not guaranteed, their values change frequently and past performance may not be repeated.

About Dynamic Funds
Dynamic Funds is a division of 1832 Asset Management L.P., which offers a range of wealth management solutions, including mutual funds, actively managed ETFs, investment solutions for private clients, institutional clients and managed asset programs. 1832 Asset Management L.P. is a limited partnership, the general partner of which is wholly owned by Scotiabank. ® Dynamic Funds is a registered trademark of its owner, used under license.

Website:

www.dynamic.ca
 | Twitter:@DynamicFunds | LinkedIn: https://www.linkedin.com/company/dynamic-funds/

SOURCE Dynamic Funds

Creatd’s Vocal Platform Hits Key Milestone of Over 25,000 Paid Subscribers

– The Vocal platform has grown its premium subscribers to over 25K since the launch of Vocal+ in Q1 2020.

– The Company reaffirms its expectation to reach over 100,000 Vocal+ subscribers by year-end 2021.

PR Newswire

FORT LEE, N.J., May 17, 2021 /PRNewswire/ — Creatd, Inc. (Nasdaq CM: CRTD) (“Creatd” or the “Company”), the parent company of Vocal, today announced that its premium membership program, Vocal+, has surpassed 25,000 subscribers. Commented Creatd CEO Jeremy Frommer, “In less than a year-and-a-half since we first rolled out Vocal+, over 25,000 creators have opted to upgrade to a premium membership. We’re seeing creators increasingly recognize Vocal as their home base, an all-in-one solution to their content needs.”

Continued Frommer, “With our current slate of upcoming Vocal Challenges, an initiative that has proven to accelerate the adoption of Vocal+ subscriptions, we can conservatively estimate reaching between 30,000 and 35,000 subscribers by the end of second quarter 2021. Our goal for the third quarter 2021 is to break 50,000 subscribers at a minimum, to as many as 65,000 subscribers at the high end of our expectations. At that point, as our brand relationships continue to expand and our costs of subscriber acquisition continue to decrease, we will be well within grasp of achieving 100,000 Vocal+ subscribers by year end 2021.”

About Creatd, Inc.

Creatd, Inc. (Nasdaq CM: CRTD) is a creator-first technology company and the parent company of the Vocal platform. Our mission is to empower creators, entrepreneurs, and brands through technology and partnership. We accomplish this through Creatd’s three main business pillars: Vocal Ventures, Creatd Partners, and Recreatd.

For news and updates, subscribe to Creatd’s newsletter: https://creatd.com/newsletter

Investor Relations Contact: [email protected]

Forward-Looking Statements

Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “intends,” “plans,” “believes” and “projects”) may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release is qualified in its entirety by the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/creatds-vocal-platform-hits-key-milestone-of-over-25-000-paid-subscribers-301292511.html

SOURCE Creatd, Inc.

IIROC Trading Halt – HELX

Canada NewsWire

VANCOUVER, BC, May 17, 2021 /CNW/ – The following issues have been halted by IIROC:

Company: Helix Applications Inc.

TSX-Venture Symbol: HELX

All Issues: Yes

Reason: At the Request of the Company Pending News

Halt Time (ET): 9:13 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Carnival Corporation Brands Resume Cruising in Europe, Caribbean

Seven leading cruise line brands from the world’s largest cruise company are resuming from global ports this summer with gradual, phased-in voyages and enhanced health protocols

Series of initial sailings build on recent restarts of company’s Germany-based AIDA Cruises and Italy-based Costa Cruises brands, which have already resumed guest cruise operations in Europe

PR Newswire

MIAMI, May 17, 2021 /PRNewswire/ — Seven cruise line brands from Carnival Corporation & plc (NYSE/LSE: CCL; NYSE: CUK), the world’s largest cruise company, have announced plans to resume guest cruise operations this summer, with AIDA Cruises, Costa Cruises, Cunard, Holland America Line, Princess Cruises, Seabourn and P&O Cruises (UK) sailing from global ports in Europe and the Caribbean.

Additionally, as the company continues to work with authorities to resume sailing in the U.S., its Carnival Cruise Line brand has announced possible U.S. restart plans and hopes to begin operating sailings in July on three ships from ports in Miami and Galveston, Texas. The company and several of its brands are also hopeful that cruises will be allowed to sail to Alaska for part of the summer.

Collectively, the brands resuming sailings from global ports over the next several months will be using a gradual, phased-in approach, including limited itineraries that have been announced on 16 initial ships to date, representing nearly 20% of the company’s global fleet. The initial cruises will take place with adjusted passenger capacity and enhanced health protocols developed in conjunction with government and health authorities, and informed by guidance from the company’s public health, epidemiological and policy experts.

Three Carnival Corporation brands – P&O Cruises (UK), Cunard and Princess Cruises – will each offer a series of cruises this summer sailing around UK coastal waters, including the inaugural sailing for P&O Cruises’ new flagship, Iona. Cruises will also resume this summer around the Greek Islands with four of the company’s brands – AIDA Cruises, Costa Cruises, Holland America Line and Seabourn. Additionally, Seabourn has announced plans to restart in the Caribbean with a series of new summer sailings out of Barbados.

The newly announced voyages build on recent cruising restarts from the company’s Germany-based AIDA Cruises brand, which resumed in late March sailing in the Canary Islands, and its Italy-based Costa Cruises brand, which restarted in May sailing to Italian ports. In addition to dozens of successful sailings from both brands in 2020, the most recent 2021 sailings from AIDA and Costa have demonstrated the effectiveness of enhanced health protocols developed in conjunction with local, national and global experts, and have generated high guest satisfaction scores, measured by detailed net promotor surveys.

“For all of our brands, our highest responsibility and top priorities are always compliance, environmental protection, and the health, safety and well-being of our guests, our shipboard and shoreside employees, and the communities we visit,” said Roger Frizzell, chief communications officer for Carnival Corporation. “We are excited to have the majority of our leading cruise line brands resume sailings this summer, as we are seeing strong pent-up demand from our past guests and consumers in general to get away on a cruise, one of the world’s most popular vacations.”

Added Frizzell: “The resumption of our cruises marks a critical step in the recovery of our brands and the industry as a whole, which provides a major economic impact and supports jobs across multiple sectors around the world. As our cruise line brands gradually resume cruising, we will continue to work as an industry to share important learnings and best practices to help ensure the resumption of cruise operations is done in the best interest of public health.”

In working with global and national health authorities and medical experts, as well as authorities in destination countries, the company’s brands have developed a comprehensive set of health and safety protocols for protection and mitigation across the entire cruise experience for its initial cruises. This includes cross-industry learnings and best practices based on the proven health and safety record of industrywide sailings and input from top science and health experts and health authorities.

Below is a brief summary of Carnival Corporation’s brands resuming guest cruise operations from global ports this summer:

AIDA Cruises

Germany-based AIDA Cruises restarted sailing in the Canary Islands with AIDAperla on March 20, with the season extending through July and offering new voyages departing from Las Palmas, Gran Canaria. Two additional ships, AIDAsol and AIDAblu, will restart at the end of May in Germany and Greece, respectively, with short voyages from Kiel, Germany, starting May 22 and seven-day cruises through the Greek Islands from May 23. In July, AIDA Cruises will launch additional new voyages in Germany, with AIDAsol departing from Rostock-Warnemünde through July 18, followed by a fourth ship, AIDAprima, which will restart on July 3, offering seven-day voyages departing from Kiel through October 23. All cruises are carried out in compliance with AIDA’s enhanced health and safety protocols, which have been tested by SGS Institut Fresenius, confirmed by the classification society DNV GL and are in compliance with applicable laws and regulations.

Costa Cruises

Italy-based Costa Cruises resumed its cruise operations on May 1 with flagship Costa Smeralda sailing a week-long all-Italian itinerary, officially kicking off the brand’s summer season, which will see a total of four Costa ships cruising in the Mediterranean. A second ship, Costa Luminosa, resumed sailing with week-long cruises to Greece on May 16, and will be followed by Costa Deliziosa on June 26, which will also offer one-week cruises to Greece. On July 4, the brand’s new ship, Costa Firenze, will debut with a one-week itinerary in Italy, in addition to one-week international cruises from September 12 until mid-October. Alongside the debut of Costa Firenze, from July 3 Costa Smeralda will be back on international itineraries, with one-week cruises in Italy, France and Spain. All sailings will follow the procedures set out in the Costa Safety Protocol, developed by Costa together with scientific experts and Italian authorities, which includes enhanced health and safety measures for all aspects of the cruise experience, both on board and ashore.

P&O Cruises UK
P&O Cruises (UK), Britain’s favorite cruise line, will resume operations with two of its ships sailing roundtrip from Southampton around the UK coast between June and September. The first of the brand’s cruises is set to begin on June 27, with a series of “short breaks” on flagship Britannia through September 19. On August 7, the brand’s new flagship Iona will depart on its seven-night maiden voyage around the coast of the island of Iona and the Scottish Isles, offering itineraries running to September 18. Given the advanced progress of the UK vaccination program, and strong expressed preference on the part of guests for this limited series of UK coastal cruises, these sailings on Britannia and Iona will be for UK resident COVID-19 vaccinated guests only. All guests and crew will be required to follow P&O Cruises’ enhanced health and well-being measures to protect everyone on board. These have been developed with guidance from global medical and public health experts and scientists and in close coordination with UK government agencies.

Seabourn
Seabourn, the company’s ultra-luxury brand, will resume its cruise operations in Greece beginning July 3, with a series of sailings on Seabourn Ovation operating roundtrip from Athens throughout the Greek Isles. A second ship, Seabourn Odyssey, will restart on July 18 with a series of new summer voyages operating roundtrip out of Bridgetown, Barbados, and visiting Antigua, the British Virgin Islands, Dominica, Grenada, St. Lucia, St. Maarten and St. Kitts. These series of voyages are open to any guests who are fully vaccinated against COVID-19. Seabourn guests will be required to comply with all health protocols that may be in place at the time of their departure. More details on Seabourn’s protocols are available here.

Princess Cruises
Princess Cruises, the world’s leading international premium cruise line, will resume operations with two of its ships in the UK, with a series of Seacations on MedallionClass ships, Regal Princess and Sky Princess, sailing roundtrip from Southampton around the UK coast through late September. The first of the brand’s ships, Regal Princess, will offer 14 UK voyages beginning July 31, followed by Sky Princess on August 30, which will offer eight UK cruises. Given the advanced progress of the UK vaccination program and strong expressed preference on the part of guests for this limited series of UK coastal cruises, these sailings on Regal Princess and Sky Princess will be available for UK resident COVID-19 vaccinated guests only. All guests and crew will be required to follow Princess Cruises’ enhanced health and well-being measures to protect everyone onboard. These have been developed with guidance from global medical and public health experts and scientists and in close coordination with UK government agencies.

Cunard
The company’s Cunard brand will restart sailing for UK guests with a series of UK voyages on board Queen Elizabeth. The voyages will be roundtrip from Southampton between July and October, and include British Isles scenic sailings along Britain’s coastline as well as special Sun Voyages, lasting between three and 12 nights. Given the advanced progress of the UK vaccination program, and strongly expressed preference on the part of guests for this limited series of UK coastal cruises, these sailings on Queen Elizabeth will be for UK resident COVID-19 vaccinated guests only. All guests and crew will be required to follow Cunard’s enhanced health and well-being measures to protect everyone onboard. These have been developed with guidance from global medical and public health experts and scientists and in close coordination with UK government agencies.

Holland America Line
Working in close coordination with the government of Greece, Holland America Line, the leader in premium cruising, will restart cruising from Athens in August with four seven-day departures aboard Eurodam. This first of the brand’s voyages will depart August 15, visiting several ports in the Greek Isles. A second unique itinerary departs August 22 to a different set of Greek ports. A seven-day itinerary will also depart Sept. 5 from Athens to Venice, Italy, with calls in Greece and Sarandë, Albania. These sailings from Greece are available for guests who have received their final dose of an approved COVID-19 vaccine at least 14 days prior embarkation and have proof of vaccination. Holland America Line guests will be required to comply with all health and safety protocols in place at the time of departure for travel to and from the ship, as well as all onboard protocols and procedures for visiting ports. Additional preventive health measures under Holland America Line’s “Travel Well” program will be in place.

Gray Line Alaska
In addition to the newly announced voyages, Holland America Line and Princess Cruises offer land-based vacation options this summer through Gray Line Alaska. Travelers may experience Alaska through a combination of escorted, explorer and rail tours, and lodging and sightseeing, between Kenai, Anchorage, Denali and Fairbanks, Alaska.

About Carnival Corporation & plc
Carnival Corporation & plc is one of the world’s largest leisure travel companies with a portfolio of nine of the world’s leading cruise lines sailing to all seven continents. With operations in North America, Australia, Europe and Asia, its portfolio features Carnival Cruise Line, Princess Cruises, Holland America Line, Seabourn, P&O Cruises (Australia), Costa Cruises, AIDA Cruises, P&O Cruises (UK) and Cunard.

Additional information can be found on www.carnivalcorp.com, www.carnival.com, www.princess.com, www.hollandamerica.com, www.seabourn.com, www.pocruises.com.au, www.costacruise.com, www.aida.de, www.pocruises.com and www.cunard.com.

Cision View original content:http://www.prnewswire.com/news-releases/carnival-corporation-brands-resume-cruising-in-europe-caribbean-301292558.html

SOURCE Carnival Corporation & plc

Cornerstone Strategic Value Fund, Inc. Announces Completion of Rights Offering

NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) — Cornerstone Strategic Value Fund, Inc. (the “Fund”) (NYSE American: CLM) is pleased to announce the completion of its one-for-three rights offering which expired on Friday, May 14, 2021 (the “Offering”). The Offering was over-subscribed. Under the terms of the Offering, record date stockholders were entitled to purchase one newly issued share of common stock of the Fund for every three rights held. The subscription price for each newly issued share was determined to be $10.64 which, under the terms of the prospectus, was equal to the greater of (i) 107% of net asset value per share as calculated at the close of trading on the date of expiration of the Offering and (ii) 80% of the market price per share at such time.

Based on preliminary results provided by the Fund’s subscription agent, the Fund received requests for approximately $420 million of its shares.

The subscription price is lower than the original estimated subscription price of $10.88. Under the prospectus, any excess payment received from a stockholder will, unless otherwise indicated on the subscription certificate received from such stockholder, be applied towards the purchase of unsubscribed shares. It is anticipated that shares will be issued on or about Thursday, May 20, 2021. Stockholders are encouraged to contact their broker regarding the specifics of their account. Newly issued shares will not be entitled to the Fund’s distribution to stockholders for the month of May 2021.

Cornerstone Strategic Value Fund, Inc. is a closed-end, diversified management investment company and is registered with the U.S. Securities & Exchange Commission (“SEC”) under the Investment Company Act of 1940, as amended.

Cornerstone Strategic Value Fund, Inc. is traded on the NYSE American under the trading symbol “CLM”. The Fund’s investment adviser is Cornerstone Advisors, Inc., which also serves as the investment adviser to another closed-end fund, Cornerstone Total Return Fund, Inc. (NYSE American: CRF). For more information regarding Cornerstone Strategic Value Fund, Inc. or Cornerstone Total Return Fund, Inc. please visit www.cornerstonestrategicvaluefund.com, and www.cornerstonetotalreturnfund.com.

Past performance is no guarantee of future performance. An investment in the Fund is subject to certain risks, including market risk. In general, shares of closed-end funds often trade at a discount from their net asset value and at the time of sale may be trading on the exchange at a price that is more or less than the original purchase price or the net asset value. An investor should carefully consider the Fund’s investment objective, risks, charges and expenses. Please read the Fund’s disclosure documents before investing.

In addition to historical information, this report contains forward-looking statements, which may concern, among other things, domestic and foreign markets, industry and economic trends and developments and government regulation and their potential impact on the Fund’s investment portfolio. These statements are subject to risks and uncertainties, including the factors set forth in the Fund’s disclosure documents, filed with the SEC, and actual trends, developments and regulations in the future and their impact on the Fund could be materially different from those projected, anticipated or implied. The Fund has no obligation to update or revise forward-looking statements.



Contact: (866) 668-6558